Rats, dogs, ruminants and poultry readily metabolise cyhalofop-butyl by hydrolysis to the acid. Depending on the animal, the acid may also break down to other metabolites. The acid and any additional degradates are then rapidly excreted. Residue levels of cyhalofop-butyl and its metabolites are low in milk, eggs and tissues.
Two male beagle dogs/group were dosed orally by gavage with 1 mg/kg of alpha-14C-/cyhalofop-butyl/ (radiochemical purity: >97%) mixed with unlabeled /cyhalofop-butyl/ (purity: 97%). ...The test material was hydrolyzed to n-butanol and /cyhalofop-butyl acid/, constituting 80% and 66% of the recovered radiolabel in the urine and feces, respectively, during the first 48 hours post-dose. In the feces, acid was further decarboxylated to form a diphenol (DP). This moiety constituted 13.2% of the recovered radiolabel. Treatment of the unidentified radiolabeled compounds with b-glucuronidase/arylsulfatase resulted in an increase of the acid and DP fractions with a corresponding decrease in these unidentified compounds.
Organic nitriles are converted into cyanide ions through the action of cytochrome P450 enzymes in the liver. Cyanide is rapidly absorbed and distributed throughout the body. Cyanide is mainly metabolized into thiocyanate by either rhodanese or 3-mercaptopyruvate sulfur transferase. Cyanide metabolites are excreted in the urine. (L96)
Organic nitriles decompose into cyanide ions both in vivo and in vitro. Consequently the primary mechanism of toxicity for organic nitriles is their production of toxic cyanide ions or hydrogen cyanide. Cyanide is an inhibitor of cytochrome c oxidase in the fourth complex of the electron transport chain (found in the membrane of the mitochondria of eukaryotic cells). It complexes with the ferric iron atom in this enzyme. The binding of cyanide to this cytochrome prevents transport of electrons from cytochrome c oxidase to oxygen. As a result, the electron transport chain is disrupted and the cell can no longer aerobically produce ATP for energy. Tissues that mainly depend on aerobic respiration, such as the central nervous system and the heart, are particularly affected. Cyanide is also known produce some of its toxic effects by binding to catalase, glutathione peroxidase, methemoglobin, hydroxocobalamin, phosphatase, tyrosinase, ascorbic acid oxidase, xanthine oxidase, succinic dehydrogenase, and Cu/Zn superoxide dismutase. Cyanide binds to the ferric ion of methemoglobin to form inactive cyanmethemoglobin. (L97)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
致癌物分类
对人类不具有致癌性（未被国际癌症研究机构IARC列名）。
No indication of carcinogenicity to humans (not listed by IARC).
来源:Toxin and Toxin Target Database (T3DB)
毒理性
毒性数据
大鼠LC50 >5,630毫克/立方米
LC50 (rat) >5,630 mg/m3
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
/SRP:/ Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/
Male and female Fischer rats were dosed orally by gavage with alpha-14C-/cyhalofop-butyl/ (radiochemical purity: >97%) or beta-14C-/cyhalofop-butyl/ (radiochemical purity: > 97%). In Groups I and II, 5 animals/sex/dose were treated with 1 or 50 mg/kg of alpha-14C-/cyhalofop-butyl/ and urine and feces samples were collected (Group I) or blood samples (Group II) for 7 days. For Group III, bile was collected for 24 hours from 5 rats/sex/group which had been treated with either 1 mg/kg of alpha-14C-/cyhalofop-butyl/ or beta-14C-/cyhalofop-butyl/. In Group IV, 5 animals/sex/group/time point were treated with 1 or 50 mg/kg of alpha-14C-/cyhalofop-butyl/ and euthanized at 4 time points over a 7 day period for a tissue distribution study. The radiolabel was excreted predominately in the urine (86 to 94% of the administered dose) with nearly all of that amount collected in the first 24 hours post-dose. There was no apparent difference between sexes or in the dosing regimens. Peak blood levels for the 1 mg/kg treated animals were at 2 hours for the males and 0.5 hours for the females. For the 50 mg/kg treated animals, peak levels were at 4 hours for the males and at 2 hours at the females. In the bile duct cannulated animals, less of the administered dose was apparently absorbed. For the alpha-14C-/cyhalofop-butyl/ treated animals, 29 and 17% of the administered dose was recovered in the stomach contents of the males and females, respectively, at 24 hours postdosing. Otherwise, 27 and 36% was recovered in the urine and 24 and 18% was collected in the bile of the males and females, respectively. Similarly, for the beta-14C-/cyhalofop-butyl/ treated animals, 40 and 38% of the administered dose was recovered in the stomach contents, 21 and 37% in the urine and 12 to 17% in the bile of the males and females, respectively at 24 hours post-dose. The radiolabel was predominately distributed in the plasma, kidneys, liver and stomach with peak tissue levels noted at 2 hours for the males and 0.5 hours for the females in the 1 mg/kg group, and 4 hours for the males and 2 hours for the females in the 50 mg/kg group. The pharmacokinetic parameters were as follows: dose 1 mg/kg, Cmax, males, 1.23 to 1.30 ug eq./mL, females, 0.58 to 0.73 ug eq./mL, Tmax, males, 2 hours, females, 0.5 hours, half-life, males, 3.0 to 3.1 hours, females, 1.4 to 3.9 hours.
On the base of the studies conducted, the mean predicted human dermal absorption values for the concentrate and spray are 1.3% and 11%, while the maximum predicted dermal absorption values for the concentrate and spray are 1.5% and 14%, respectively.
我们报告了在可见光照射下使用 Ir 光催化剂对 N-羟基邻苯二甲酰亚胺酯进行亲核氟化的氧化还原中性方法。该方法提供了获得广泛的脂肪族氟化物的途径，包括伯、仲和叔苄基氟化物以及未活化的叔氟化物，由于竞争消除，这些氟化物通常无法通过亲核氟化获得。此外，我们表明脱羧氟化条件很容易适应 [18F]KF 的放射性氟化。我们建议反应通过 Ir 催化剂和氧化还原活性酯底物之间的两次电子转移进行，以提供碳阳离子中间体，随后被氟化物捕获。
[EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
申请人：GILEAD APOLLO LLC
公开号：WO2017075056A1
公开（公告）日：2017-05-04
The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
[EN] 3-[(HYDRAZONO)METHYL]-N-(TETRAZOL-5-YL)-BENZAMIDE AND 3-[(HYDRAZONO)METHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE DERIVATIVES AS HERBICIDES<br/>[FR] DÉRIVÉS DE 3-[(HYDRAZONO))MÉTHYL]-N-(TÉTRAZOL-5-YL)-BENZAMIDE ET DE 3-[(HYDRAZONO)MÉTHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE UTILISÉS EN TANT QU'HERBICIDES
申请人：SYNGENTA CROP PROTECTION AG
公开号：WO2021013969A1
公开（公告）日：2021-01-28
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4, R5 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to methods of controlling weeds using said compositions, and to the use of compounds of Formula (I) as a herbicide.
[EN] HERBICIDALLY ACTIVE HETEROARYL-S?BSTIT?TED CYCLIC DIONES OR DERIVATIVES THEREOF<br/>[FR] DIONES CYCLIQUES SUBSTITUÉES PAR HÉTÉROARYLE À ACTIVITÉ HERBICIDE OU DÉRIVÉS DE CELLES-CI
申请人：SYNGENTA LTD
公开号：WO2011012862A1
公开（公告）日：2011-02-03
The invention relates to a compound of formula (I), which is suitable for use as a herbicide wherein G is hydrogen or an agriculturally acceptable metal, sulfonium, ammonium or latentiating group; Q is a unsubstituted or substituted C3-C8 saturated or mono-unsaturated heterocyclyl containing at least one heteroatom selected from O, N and S, or Q is heteroaryl or substituted heteroaryl; m is 1, 2 or 3; and Het is an optionally substituted monocyclic or bicyclic heteroaromatic ring; and wherein the compound is optionally an agronomically acceptable salt thereof.
The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
本发明提供了三唑化合物，可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及其组合物和使用方法。
3-AMINOXALYL-AMINOBENZAMIDE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENTS CONTAINING SAME AS ACTIVE INGREDIENT
申请人：Usui Shuichi
公开号：US20120022263A1
公开（公告）日：2012-01-26
The present invention herein provides a 3-aminooxalylaminobenzamide derivative which is used as an insecticide or miticide.
The 3-aminooxalylaminobenzamide derivative is one represented by the following general formula [1]:
(R
1
and R
2
each represent, for instance, a C
1
to C
3
alkoxy group or a C
1
to C
3
haloalkoxy group; R
3
and R
4
each represent, for instance, a C
1
to C
8
alkyl group or a C
1
to C
8
haloalkyl group; R
5
represents, for instance, a C
1
to C
5
haloalkyl group; R
6
and R
7
each represent, for instance, a hydrogen atom or a C
1
to C
5
alkyl group; Y represents, for instance, a hydrogen atom or a halogen atom; Z represents, for instance, a hydrogen atom; n is an integer ranging from 0 to 4 and m is an integer ranging from 0 to 2).
